Intracerebral Hemorrhage Outcomes in Patients with Systemic Cancer

详细信息    查看全文

• 作者：Santosh B. Murthy ; MD ; MPH^* ; ^&dagger ; ; ^{sam9200@med.cornell.edu} ; Aditi Shastri ; MD^&Dagger ; ; Alexander E. Merkler ; MD^* ; Daniel F. Hanley ; MD^§ ; ; Wendy C. Ziai ; MD ; MPH^‖ ; Matthew E. Fink ; MD^* ; Costantino Iadecola ; MD^* ; ^&dagger ; ; Hooman Kamel ; MD^* ; ^&dagger ; ; Babak B. Navi ; MD ; MS^* ; ^&dagger ;
• 关键词：Intracerebral hemorrhage ; cancer ; malignancy ; clinical outcomes
• 刊名：Journal of Stroke and Cerebrovascular Diseases
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：25
• 期：12
• 页码：2918-2924
• 全文大小：147 K
• 卷排序：25

文摘

Single-center studies suggest that patients with cancer have similar outcomes after intracerebral hemorrhage (ICH) compared to patients without cancer. However, these studies were limited by small sample sizes and high rates of intratumoral hemorrhage. Our hypothesis was that systemic cancer patients without brain involvement fare worse after ICH than patients without cancer.MethodsWe identified all patients diagnosed with spontaneous ICH from 2002 to 2011 in the Nationwide Inpatient Sample. Our predictor variable was systemic cancer. Our primary outcome was discharge disposition, dichotomized into favorable discharge (home/self-care or rehabilitation) or unfavorable discharge (nursing facility, hospice, or death). We used logistic regression to compare outcomes and performed secondary analyses by cancer subtype (i.e., nonmetastatic solid tumors, nonmetastatic hematologic tumors, and metastatic solid or hematologic tumors).ResultsAmong 597,046 identified ICH patients, 22,394 (3.8%) had systemic cancer. Stroke risk factors such as hypertension and diabetes were more common in patients without cancer, whereas anticoagulant use and higher Charlson comorbidity scores were more common among cancer patients. In multivariate logistic regression analysis adjusted for demographics, comorbidities, and hospital-level characteristics, patients with cancer had higher odds of death (OR 1.62, 95% CI 1.56-1.69) and lower odds of favorable discharge (OR .59, 95% CI .56-.63) than patients without cancer. Among cancer groups, patients with nonmetastatic hematologic tumors and those with metastatic disease fared the worst.ConclusionsPatients with systemic cancer have higher mortality and less favorable discharge outcomes after ICH than patients without cancer. Cancer subtype may influence outcomes after ICH.